Who is sponsoring NCT03050424?

NCT03050424 is sponsored by Royal Brompton & Harefield NHS Foundation Trust.

What drugs are being tested in NCT03050424?

Interventions in NCT03050424: Ferric Carboxymaltose, Sodium Chloride 0.9%.

What condition does NCT03050424 study?

NCT03050424 studies Chronic Obstructive Pulmonary Disease.

Is NCT03050424 still recruiting?

NCT03050424 is currently status unknown. Last updated 12 May 2017.

Last reviewed 2017-05-12 · How we verify

NCT03050424: ICE-T

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial

Status unknown Phase 2 Last updated 12 May 2017

What this trial tests

Phase 2 trial testing Ferric Carboxymaltose in Chronic Obstructive Pulmonary Disease in 40 participants. Status unknown.

Timeline

1 April 2017

Primary endpoint
1 October 2018

1 January 2019

Quick facts

Lead sponsor	Royal Brompton & Harefield NHS Foundation Trust
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	1 April 2017
Primary completion	1 October 2018
Estimated completion	1 January 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

Ferric Carboxymaltose (FERRIC CARBOXYMALTOSE) — full drug profile →
Sodium Chloride 0.9%

Conditions studied

Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →

Sponsor

Royal Brompton & Harefield NHS Foundation Trust

Who can join

Adults 18 to 100, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II single centre, double blind, placebo-controlled, randomised trial aims to test the hypothesis that intravenous iron improves exercise performance in Chronic Obstructive Pulmonary Disease (COPD) as measured by constant rate cycle ergometry.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The prevalence and associated mortality of non-anaemic iron deficiency in older adults: a 14 years observational cohort study.
Philip KEJ, Sadaka AS, Polkey MI, Hopkinson NS, et al · · 2020 · cited 30× · PMID 32072619 · DOI 10.1111/bjh.16409
Anaemia and iron dysregulation: untapped therapeutic targets in chronic lung disease?
Patel MS, McKie E, Steiner MC, Pascoe SJ, et al · · 2019 · cited 8× · PMID 31548896 · DOI 10.1136/bmjresp-2019-000454
Ferritinophagy: molecular mechanisms and its crosstalk with ferroptosis in chronic respiratory diseases.
Ning J, Wen L, Qiao L. · · 2026 · cited 2× · PMID 41629496 · DOI 10.1007/s10565-026-10150-x

Verify or expand the search:

Other trials of Ferric Carboxymaltose

Trials testing the same drug.

NCT07053475 — IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches · Phase 4 · recruiting
NCT03466983 — A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxyma · Phase 4 · completed
NCT02949947 — Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Re · Phase 2 · terminated
NCT03380520 — Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy · Phase 4 · completed
NCT03218384 — Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency · Phase 2 · terminated

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting

Other Royal Brompton & Harefield NHS Foundation Trust trials

Trials by the same sponsor.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
NCT07402434 — A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis · not yet recruiting
NCT06661278 — Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias · recruiting
NCT06519240 — A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03050424 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Brompton & Harefield NHS Foundation Trust
Last refreshed: 12 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03050424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing